Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development.
The essential biological function of phosphodiesterase (PDE) type enzymes is to regulate the cytoplasmic levels of intracellular second messengers, 3',5'-cyclic guanosine monophosphate (cGMP) and/or 3',5'-cyclic adenosine monophosphate (cAMP). PDE targets have 11 isoenzymes. Of these enzymes, PDE5 has attracted a special attention over the years after its recognition as being the target enzyme in treating erectile dysfunction. Due to the amino acid sequence and the secondary structural similarity of PDE6 and PDE11 with the catalytic domain of PDE5, first-generation PDE5 inhibitors (i.e. sildenafil and vardenafil) are also competitive inhibitors of PDE6 and PDE11. Since the major challenge of designing novel PDE5 inhibitors is to decrease their cross-reactivity with PDE6 and PDE11, in this study, we attempt to identify potent tadalafil-like PDE5 inhibitors that have PDE5/PDE6 and PDE5/PDE11 selectivity. For this aim, the similarity-based virtual screening protocol is applied for the "clean drug-like subset of ZINC database" that contains more than 20 million small compounds. Moreover, molecular dynamics (MD) simulations of selected hits complexed with PDE5 and off-targets were performed in order to get insights for structural and dynamical behaviors of the selected molecules as selective PDE5 inhibitors. Since tadalafil blocks hERG1 K channels in concentration dependent manner, the cardiotoxicity prediction of the hit molecules was also tested. Results of this study can be useful for designing of novel, safe and selective PDE5 inhibitors.
a Department of Chemistry , Istanbul Technical University , Istanbul , Turkey.|b Department of Pharmacy , University of Pisa , Pisa , Italy.
Gülru
G
Kayık
a Department of Chemistry , Istanbul Technical University , Istanbul , Turkey.
Nurcan Ş
NŞ
Tüzün
c Department of Biophysics , School of Medicine, Bahcesehir University , Istanbul , Turkey.
Serdar
S
Durdagi
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D020134:Catalytic Domain; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5 / Q000187:drug effects*; D054707:Cyclic Nucleotide Phosphodiesterases, Type 6 / Q000187:drug effects*; D006801:Humans; D008958:Models, Molecular; D015394:Molecular Structure; D058986:Phosphodiesterase 5 Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D010727:Phosphoric Diester Hydrolases / Q000187:drug effects*; D000068581:Tadalafil / Q000494:pharmacology*
D058986:Phosphodiesterase 5 Inhibitors; D000068581:Tadalafil; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D054707:Cyclic Nucleotide Phosphodiesterases, Type 6; C406737:PDE11A protein, human
E-pharmacophore modeling; molecular docking; molecular dynamics (MD) simulations; phosphodiesterase (PDE) type enzymes; virtual screening